Navigation Links
Cell signaling discovery provides new hope for blood disorders
Date:2/16/2012

Walter and Eliza Hall Institute scientists have revealed new details about how cell signalling is controlled in the immune system, identifying in the process potential new therapeutic targets for treating severe blood disorders.

Dr Jeff Babon and Professor Nick Nicola, from the institute's Structural Biology and Cancer and Haematology divisions respectively, study interactions between internal cell signalling proteins called JAKs (Janus kinases) and SOCS (Suppressors of Cytokine Signalling).

Dr Babon said the proteins were essential for blood system maintenance and immune responses.

"JAK proteins are activated in response to blood cell hormones called cytokines and instruct immune cells to respond to infection and inflammation," Dr Babon said. "SOCS proteins were discovered at the institute in the early 2000s, and provide a necessary 'negative feedback' response that stops JAKs becoming overactive, which can lead to disease."

Dr Babon said mutations in one particular protein, JAK2, are strongly associated with the development of myeloproliferative diseases.

"When JAK2 is mutated, it tells cells to continually multiply. An excessive amount of blood cells of one type are produced, and the bone marrow is overrun, leading to problems with production of other cell types, and eventually bone marrow failure," Dr Babon said.

Myeloproliferative diseases, such as polycythemia vera and essential thrombocytopenia, are serious blood disorders in which an excessive number of blood cells accumulate in the bone marrow. They can be very severe and sometimes fatal, and may progress to acute leukaemias.

In a study published today in the journal Immunity, Dr Babon and Professor Nicola, with colleagues Dr James Murphy and Dr Nadia Kershaw, report on a key discovery about how the proteins JAK2 and SOCS3 interact. They hope the discovery will lead to new strategies for treating myeloproliferative diseases.

"SOCS3 is a key inhibitor of JAK2 proteins in blood and immune cells, but we didn't know exactly how the two proteins interacted to suppress JAK2 function," Dr Babon said. "We wanted to identify which site the SOCS3 protein bound to on the JAK2 protein to inhibit its action, and were surprised to find that SOCS3 binds to a unique site on JAK2 and directly inhibits the protein, rather than outcompeting other molecules."

Dr Babon said the finding could inspire a new class of therapeutic agents for treating myeloproliferative diseases.

"The SOCS3 binding site is a previously unknown part of the JAK2 protein which could be exploited as a drug target, with greater specificity than other drugs that are currently in clinical trials for inhibiting JAK2," he said.


'/>"/>
Contact: Liz Williams
williams@wehi.edu.au
61-405-279-095
Walter and Eliza Hall Institute
Source:Eurekalert

Related medicine news :

1. Plant flavonoid luteolin blocks cell signaling pathways in colon cancer cells
2. Cell signaling key to stopping growth and migration of brain cancer cells
3. Insulin signaling is distorted in pancreases of Type 2 diabetics
4. Unexpected signaling role for foul-smelling hydrogen sulfide in cell response to protein misfolding
5. New gene study of ADHD points to defects in brain signaling pathways
6. Unraveling the complex signaling that helps cells know when to grow, when to sit tight
7. How major signaling pathways are wired to our genome gives new insight into disease processes
8. Stem cells, signaling pathways identified in lung repair
9. Signaling molecule identified as essential for maintaining a balanced immune response
10. NYU researchers develop compound to block signaling of cancer-causing protein
11. Roadmap published for dynamic mapping of estrogen signaling in breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... , ... New patients with missing teeth in Fitchburg, WI, can ... Dr. Cotey is a trusted dentist who has placed many dental implants and enjoys ... missing teeth in Fitchburg, WI, are encouraged to find out if they are candidates ...
(Date:6/25/2017)... ... June 25, 2017 , ... Republicans in the United States Senate ... called the Better Care Reconciliation Act. It differs significantly from the American Health Care ... be reconciled in committee, or the House will have to take up the Senate ...
(Date:6/25/2017)... , ... June 25, 2017 , ... With a heatwave currently bearing down on Northern ... out at the pool. Being swimsuit ready is easy with laser hair removal. , ... again can be a burdensome routine when all you want to do is get out, ...
(Date:6/24/2017)... ... June 24, 2017 , ... The Pennsylvania Athletic ... Erie Bayfront and Erie Convention Center on June 8-10. The weekend consisted ... quiz bowl, award and scholarship presentations, and professional networking. , On Friday ...
(Date:6/24/2017)... ... ... Doorknobs are for convenience, deadbolts are for security. , There are many ... an alarm system installed. But unless there is a working deadbolt lock that is ... Premier Locksmith in Killeen, TX says: “In the majority of home burglaries, intruders use ...
Breaking Medicine News(10 mins):
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
(Date:6/8/2017)...  Less than a month ago, amateur hackers executed ... including hospital networks, in over 150 countries. ... largest online extortion attempts ever recorded. With the increasing ... imperative that providers understand where the risks lie, and ... and many other very real cyber threats.  ...
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
Breaking Medicine Technology: